FNY Investment Advisers LLC Acquires 294,323 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

FNY Investment Advisers LLC raised its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 160.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 477,823 shares of the biopharmaceutical company's stock after purchasing an additional 294,323 shares during the period. FNY Investment Advisers LLC owned 0.46% of Revance Therapeutics worth $1,452,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. LMR Partners LLP bought a new stake in shares of Revance Therapeutics in the third quarter valued at about $11,648,000. Integral Health Asset Management LLC acquired a new position in shares of Revance Therapeutics during the 2nd quarter worth approximately $1,285,000. Oddo BHF Asset Management Sas bought a new position in shares of Revance Therapeutics during the third quarter worth approximately $3,763,000. Alpine Associates Management Inc. acquired a new stake in shares of Revance Therapeutics in the third quarter valued at approximately $21,605,000. Finally, Wellington Management Group LLP bought a new stake in shares of Revance Therapeutics in the third quarter valued at approximately $2,315,000. 97.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RVNC has been the subject of several analyst reports. StockNews.com assumed coverage on Revance Therapeutics in a report on Monday. They issued a "hold" rating for the company. HC Wainwright reaffirmed a "neutral" rating and issued a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Needham & Company LLC reissued a "hold" rating on shares of Revance Therapeutics in a report on Friday, November 8th. Barclays cut their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an "equal weight" rating for the company in a report on Monday, December 23rd. Finally, Mizuho decreased their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating on the stock in a research note on Tuesday, December 10th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $8.39.

Revance Therapeutics Stock Performance

Revance Therapeutics stock remained flat at $3.29 during mid-day trading on Tuesday. 698,619 shares of the company's stock were exchanged, compared to its average volume of 3,706,865. The company has a fifty day moving average of $3.56 and a two-hundred day moving average of $4.55. The firm has a market cap of $343.44 million, a P/E ratio of -1.70 and a beta of 0.86. Revance Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $7.56.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. Sell-side analysts predict that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.